**Question:** A 55 year old male patient was diagnosed to have chronic hepatitis C. He responded to treatment with interferon. However, after one year of follow up he showed a relapse of disease. Which of the following would be the next most appropriate choice?

A. Antiviral treatment with a more potent drug
B. Liver transplantation
C. Monitoring for side effects and adjusting treatment regimen
D. Increasing the dosage of interferon

**Correct Answer:**

**Core Concept:** Chronic hepatitis C is a viral infection caused by the hepatitis C virus (HCV) that affects the liver. Interferon is a cytokine used as a treatment for chronic hepatitis C. Relapse occurs when the patient becomes infected again after initially responding to treatment.

**Why the Correct Answer is Right:** Relapse in hepatitis C treatment is a common issue, especially when using interferon as monotherapy. In this case, the next most appropriate choice would be to consider a more potent antiviral drug as combination therapy. Combination therapy with pegylated interferon and ribavirin has been proven to improve treatment outcomes and reduce relapses.

**Why Each Wrong Option is Incorrect:**

**Option A (Antiviral treatment with a more potent drug):**
While it is true that using a more potent drug may improve treatment outcomes, increasing the dosage of interferon is not the correct approach as interferon is a cytokine, not a drug. Cytokines are signaling molecules produced by the immune system, not drugs that can be titrated in the same way as medications.

**Option B (Liver transplantation):**
While liver transplantation is a potential treatment option for end-stage liver disease caused by chronic hepatitis C, it is not the most appropriate choice when dealing with a relapsing case after initial response to interferon monotherapy. Transplantation is usually considered in severe cases where interferon therapy has failed or is contraindicated.

**Option D (Increasing the dosage of interferon):**
As mentioned above, interferon is a cytokine and cannot be titrated like a medication. Increasing the dosage would not address the issue of interferon monotherapy failure and may lead to unnecessary side effects without improving the treatment outcome.

**Clinical Pearl:** Combination therapy involving more than one antiviral agent is the standard of care for chronic hepatitis C treatment. Pegylated interferon and ribavirin are commonly used in combination, reducing the risk of relapse and improving overall treatment success rates.